Tandem High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Brain Tumors
Central nervous system (CNS) tumors are the second most common pediatric malignancies with an about 25% 5-year overall survival rate in high-risk group. Children under 4 year have very bad prognosis. We tried to assess the effectiveness of tandem high-dose chemotherapy (HDCT) with autologous hematopoietic stem-cell transplantation (auto-HSCT) in this patient group.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Asmik Gevorgian, Elena Morozova, Ilya Kazantsev, Tatiana Iukhta, Svetlana Safonova, Yury Punanov, Ludmila Zubarovskaya, Olga Zheludkova, Boris Afanasyev Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Children | Leukemia | Lymphoma | Myeloma | Neurology | Pediatrics | Stem Cell Therapy | Stem Cells | Transplants